From the Journals

What Drives Progression Despite TNFi?

Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.

Share

A recent study published in RMD Open investigated the relationship between complement system activation and radiographic progression in axial spondyloarthritis (axSpA). This research, based on a longitudinal randomized controlled trial involving 96 patients undergoing tumor necrosis factor inhibitor (TNFi) therapy, found that elevated serum levels of complement proteins like C3dg and MASP-1 at baseline were predictive of new bone formation in patients after 2 years. This highlights the connection between complement activation and spinal progression in axSpA patients.

Original Source(s)

What Drives Progression Despite TNFi?

Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.

  • by Julie Greenbaum

  • December 11, 2025

  • 2 min

Related Content

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."